Thursday 3 July 2014

A deal inked between Sysmex and Bayer

Sysmex and Bayer inked a deal that made customized drug yet an alternate stride forward. The Japanese diagnostics titan and the German drugmaker will create companion diagnostic tests intended for focused cancer treatment.

Not, one or the other side is uncovering budgetary subtle elements, however they'll bring out their understanding through subsidiaries. The arrangement is to match blood-based partner symptomatic tests created by Sysmex's recently gained Inostics division with focused anti-cancer drugs advanced by Bayer HealthCare.

Their organization will depend vigorously on Sysmex Inostics' Beaming innovation, which empowers to a great degree sensitive diagnostics tests that can screen for circling tumor DNA push off into the circulation system in a procedure known as a "fluid biopsy." It's intended to be a non-intrusive option to routine biopsies, where a bit of a tumor must be uprooted and tried. Sysmex grabbed up Inostics in late September, which had been possessed by Germany's Indivumed and has operations in Hamburg, Germany and Baltimore, MD.

"Blood-based DNA tests provide diagnostics options for cancer patients without tumor biopsies being necessary," noted Andreas Busch, head of Global Drug Discovery and member of Bayer HealthCare's Executive Committee, in a statement. "With this collaboration, we continue to strengthen our engagement in the field of personalized medicine with the aim of developing innovative therapies for cancer patients."

Likewise, companion diagnostics are presently a a usual part of drug advancement. The companion diagnostic is intended to help detect a specific transformation or hereditary quality that would chalk out patients who react best to a given medication. What's more Sysmex is wagering its manage Bayer will fuel significant growth for the organization in the partner diagnostics space.

Hence, companion diagnostic market is growing fast and its benefits are being recognized globally. A latest report shows that Companion Diagnostic market would reach a value of $3.5 billion by 2020. It would be interesting to watch the future developments of the market.

Philips and Salesforce inks a deal

There's more where that originated from. Salesforce and Philips have reported a vital association to convey a more collective healthcare framework.

In a media roundtable , the organizations uncovered two clinical applications which have as of now been made and will be accessible on the stage this hot time of year. Philips ecarecoordinator and Philips ecarecompanion will sit nearby Philips' Hospital to Home telehealth operation, enhancing what the social insurance supplier calls an "emergency" today, with in excess of 171 million individuals anticipated that will be existing with endless conditions in the US by 2030.

The result, clearly, is more noteworthy transparency and correspondence in the middle of patients and human services suppliers, with the two organizations plotting a future whereby applications will be fundamental to social insurance, from planning toward oneself and aversion to finding and medicine.

“We have entered a new transformative era for healthcare, and technology is enabling the industry to connect to, care for and engage with patients and each other in a profound new way,” said Salesforce CEO Benioff.

Salesforce included that through the open Salesforce1 stage, designers and Isvs will have the capacity to work together and construct their health awareness results, refering to Apple's Healthkit as a comparable player.

It's obviously been an occupied couple of months at Salesforce towers, with the dispatch of a UK server farm and the renaming of the Heron Tower as the Salesforce Tower, with the current stress based upon the 'Web of Customers' and the dispatch of the Salesforce1 application.

This most recent play obviously puts that on the guide, imagining a positively associated world. At the point when the Salesforce1 World Tour landed in London a month ago, the keynote talks fortified the cloud, social, portable world the organization depicts. As cloud-first was portrayed as "the new mantra in today's reality" by COO George Hu, this is an alternate venture in that course.

Salesforce's association with Philips comes in the midst of an arrangement of different partnerships, most quite with Microsoft and HP. Cloud services are increasingly being utilized in the IT world. As per AMR’s research, cloud services market would reach $555 Billion globally by 2020. 

Major breakthrough in Bio Acrylic Acids

The combined efforts of acrylic acid market major players BASF, Cargill and Novozymes have yielded a significant breakthrough in techniques to produce bio acrylic acid. The team has succeeded in producing 3-hydroxypropionic acid (3-HP) in pilot scale, which can be used as an input chemical for producing acrylic acid. “3-HP is a potential key raw material for the production of bio-based acrylic acid which is a precursor of superabsorbent polymers,” stated Teressa Szelest, Senior Vice President Global Hygiene Business at BASF. “We still have a fair amount of work to do before the process is commercially ready, but this is a significant milestone and we are confident we can continue to the next level of scale-up for the entire process in 2014.”

Since acrylic acid is conventionally produced from fossil fuels, 3-HP, being a renewable and eco-friendly resource gives a fresh lease of life to this very useful product. This breakthrough has  decreased the restraints of acrylic acids in the global markets. “Our three companies have assembled highly talented and experienced joint working teams for this project,”  stated Jack Staloch, Vice President of Biotechnology R&D at Cargill. “They’ve moved with speed and intensity, and have demonstrated great progress toward accomplishing our goals.”

 “We have reached an important milestone by producing 3-HP in pilot scale,” said Rasmus von Gottberg, Vice President of Corporate Development and Business Creation at Novozymes. “We have shown that it is possible to make this key chemical building block from renewable raw materials in robust industrial conditions. Now the development work will continue towards commercialization.”

 Such efforts from leading producers are making the acrylic acid global market all the more lucrative. As per a latest study by Allied Market Research, the global acrylic acid market is poised to reach $22.78bn by 2020. Bio-acrylic acid certainly reinforces this claim, providing a sea of opportunities to the investors.